Across TCGA pan-cancer cohorts, IFT81 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IFT81 data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher IFT81 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFT81 expression acts as an unfavorable survival marker.
COAD are the cancer types where IFT81 Mutation most reproducibly stratifies survival.